New York: Bristol Myers (NYSE:BMY) Stock Has Just Had Its Buy Rating Reiterated by UBS. Shares now Have a $72.0 Target

December 7, 2017 - By Vivian Park

 New York: Bristol Myers (NYSE:BMY) Stock Has Just Had Its Buy Rating Reiterated by UBS. Shares now Have a $72.0 Target

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It dropped, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Caprock Group Incorporated holds 0.28% or 22,927 shares. Moreover, Wetherby Asset Inc has 0.46% invested in Bristol-Myers Squibb Company (NYSE:BMY). Marietta Prtnrs Ltd Liability Corp holds 10,300 shares. Hengehold Management Ltd holds 0.28% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 17,672 shares. Foundry Lc holds 0.54% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 237,371 shares. Jfs Wealth Advsrs Ltd Liability Corporation owns 0.02% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 1,305 shares. Telos Mgmt invested 0.32% in Bristol-Myers Squibb Company (NYSE:BMY). Beacon Fincl reported 94,947 shares. Salzhauer Michael has invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, Ameritas Investment Prtn has 0.25% invested in Bristol-Myers Squibb Company (NYSE:BMY). 177,974 are held by Muhlenkamp And. 20,301 are owned by Lombard Odier Asset Mgmt (Europe). Meristem Ltd Liability Partnership reported 13,723 shares. Bokf Na reported 206,187 shares. 29,160 are owned by Woodstock.

Bristol Myers (NYSE:BMY) Rating Reaffirmed

Investment analysts at UBS now has a $72.0 target price on Bristol Myers (NYSE:BMY). UBS and their recent target price would indicate a potential upside of 16.43 % from the company’s last stock close price. The rating has been revealed to investors in an analyst report on Friday, 6 October.

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It dropped, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Caprock Group Incorporated holds 0.28% or 22,927 shares. Moreover, Wetherby Asset Inc has 0.46% invested in Bristol-Myers Squibb Company (NYSE:BMY). Marietta Prtnrs Ltd Liability Corp holds 10,300 shares. Hengehold Management Ltd holds 0.28% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 17,672 shares. Foundry Lc holds 0.54% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 237,371 shares. Jfs Wealth Advsrs Ltd Liability Corporation owns 0.02% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 1,305 shares. Telos Mgmt invested 0.32% in Bristol-Myers Squibb Company (NYSE:BMY). Beacon Fincl reported 94,947 shares. Salzhauer Michael has invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, Ameritas Investment Prtn has 0.25% invested in Bristol-Myers Squibb Company (NYSE:BMY). 177,974 are held by Muhlenkamp And. 20,301 are owned by Lombard Odier Asset Mgmt (Europe). Meristem Ltd Liability Partnership reported 13,723 shares. Bokf Na reported 206,187 shares. 29,160 are owned by Woodstock.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 1.12% above currents $61.84 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Cowen & Co on Monday, September 18. Citigroup maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, October 18. Citigroup has “Buy” rating and $72 target. The stock has “Underweight” rating by Piper Jaffray on Monday, August 24. Jefferies maintained the shares of BMY in report on Friday, September 15 with “Buy” rating. The firm earned “Hold” rating on Thursday, November 16 by Jefferies. Credit Suisse maintained it with “Neutral” rating and $61 target in Friday, October 27 report. The rating was maintained by Piper Jaffray with “Hold” on Thursday, October 26. The stock has “Market Perform” rating by BMO Capital Markets on Wednesday, April 5. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by SunTrust on Monday, October 30. The firm earned “Buy” rating on Tuesday, September 20 by Citigroup.

The stock increased 1.43% or $0.87 during the last trading session, reaching $61.84. About 5.12M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 7, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35 % or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 23.07 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67 % negative EPS growth.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $101.21 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.26 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Nasdaq.com which released: “Madrona Financial Services, LLC Buys ONEOK Inc, Boeing Co, Bristol-Myers …” on November 09, 2017, also Bloomberg.com with their article: “Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact” published on December 01, 2017, Investorplace.com published: “Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating” on November 24, 2017. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Investorplace.com and their article: “3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers …” published on December 04, 2017 as well as Investorplace.com‘s news article titled: “Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating” with publication date: December 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.